Molecular Characterization and Antimicrobial Susceptibility Study of Acinetobacter baumannii Clinical Isolates from Middle East, African and Indian Patients

Acinetobacter species are aerobic gram-negative organism being responsible for various types of infections such as pneumonia, urinary tract infection and septicemia [1-4]. The Acenitobacter infections have been recognized as an emerging problem and appeared to be associated with high mortality rates throughout the world. Very recently, it has been reported that Acinetobacter species accounts for 10% of community-acquired bacteraemia in Kenyan hospital and the prevalence of antibiotic resistance among Acinetobacter baumannii isolates in Syria have been increasing in recent years [5,6]. The overall prevalence of nosocomial infections in hospital intensive care units due to A. baumannii varies from 2 to 10% [7]. The infections caused by Acinetobacter are often treated with cephalosporins including ceftazidime, ceftriaxone, aminoglycosides such as tobramycin and amikacin, carbapenems, and tetracycline. However, to date, most strains of A. baumannii have become increasingly resistant to almost all these currently available antibacterial agents [4].